Ancora Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Ancora Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,350	Closed	-$1K	–	2233
2022 Q4	$1K	Hold	15,350	–	–	﹤0.01%	1765
2022 Q3	$1K	Hold	15,350	–	–	﹤0.01%	2008
2022 Q2	$1K	Hold	15,350	–	–	﹤0.01%	2191
2022 Q1	$4K	Buy	15,350 +10,000	+187%	+$3.19K	﹤0.01%	2044
2021 Q4	$4K	Hold	5,350	–	–	﹤0.01%	2114
2021 Q3	$4K	Buy	5,350 +300	+6%	+$223	﹤0.01%	1975
2021 Q2	$4K	Buy	+5,050	New	+$3.51K	﹤0.01%	1754

Ancora Advisors's BIOTW Position: Q1 2023 in Review

Ancora Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 15,350 shares — an estimated $1K sold.

Ancora Advisors first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $4K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Ancora Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Ancora Advisors sold 15,350 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1K.
Ancora Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
Ancora Advisors's Biotech Acquisition Company Warrant position peaked at $4K in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Ancora Advisors's 13F filing for Q1 2023, filed 16 May 2023.